{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Phase 2 Trial of Imlifidase for Desensitization in Kidney Transplantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This open-label, single-arm, phase 2 trial was conducted at five transplant centers"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult patients with a median calculated panel-reactive antibody (cPRA) of 99.83% were enrolled."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Imlifidase was administered intravenously to convert positive crossmatch tests to negative within 24 hours."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy and safety of imlifidase in converting positive crossmatch tests to negative, thus enabling transplantation."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was crossmatch conversion, with secondary outcomes including donor-specific antibody levels, renal function, and safety."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "No randomization or blinding was performed due to the study's single-arm design."
      },
      "Blinding": {
        "score": 3,
        "evidence": "No randomization or blinding was performed due to the study's single-arm design."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "This open-label, single-arm, phase 2 trial was conducted at five transplant centers (Cedars-Sinai Medical Center, The Johns Hopkins Hospital, New York University Langone Health, Uppsala University Hospital, H\u00f4pital Necker) from September 30, 2016, to July 3, 2018."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 19 enrolled patients, 18 received a full dose of imlifidase"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "89.5% achieving crossmatch conversion within 24 hours. Patient survival was 100%, and graft survival was 88.9% at 6 months."
      },
      "Harms": {
        "score": 1,
        "evidence": "Seven adverse events in six patients were related to treatment, all mild to moderate."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ClinicalTrials.gov NCT02790437."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: The study was funded by Hansa Biopharma AB."
      }
    },
    "total_score": 19,
    "max_score": 25
  },
  "model": "gpt-4o"
}